Overview

Risk Reduction for Alzheimer's Disease

Status:
Active, not recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
Physical inactivity, high blood pressure and dyslipidemia are risk factors for Alzheimer's disease (AD) and vascular dementia. Importantly, these risk factors are modifiable with lifestyle changes, pharmacological treatment, or both. The rrAD study will determine effects of aerobic exercise training and intensive vascular risk reduction on cognitive performance in older adults who have high risk for AD.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
University of Texas Southwestern Medical Center
Collaborators:
Michigan State University
Pennington Biomedical Research Center
Texas Health Resources
University of Kansas Medical Center
Washington University School of Medicine
Treatments:
Amlodipine
Angiotensin II
Angiotensin Receptor Antagonists
Angiotensinogen
Atorvastatin Calcium
Calcium
Calcium Channel Blockers
Giapreza
Losartan